The startup offers a pan-omics data analysis platform that utilizes molecular biology techniques to analyze genomes, transcriptomes, proteomes, and metabolites for drug development. This platform enables clients to enhance patient selection criteria by identifying new and companion diagnostic biomarkers for targeted therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Drug development is often hindered by inefficient patient selection, leading to increased costs and timelines. Identifying appropriate biomarkers for targeted therapies remains a challenge, delaying the development and approval of new drugs.
Solution
Virtris offers a biosimulation platform that leverages pan-omics data analysis to accelerate drug discovery and enhance patient selection for clinical trials. By integrating genomics, transcriptomics, proteomics, and metabolomics data, the platform creates virtual patients and generates synthetic control arms to simulate clinical trials in silico. This approach allows biotech and pharmaceutical companies to predict drug response, identify potential biomarkers, and optimize patient selection criteria for targeted therapies. The platform employs a combination of artificial intelligence and mechanistic modeling to design virtual patients and simulate clinical trials.
Target Audience
The primary customers are biotech and pharmaceutical companies, as well as academic institutions, involved in drug discovery and clinical trials.
Features
- Pan-omics data integration and analysis for comprehensive molecular profiling
- AI-driven virtual patient creation for in silico clinical trial simulations
- Predictive modeling of drug response based on patient-specific omics data
- Biomarker identification for enhanced patient selection in clinical trials
- Support for various disease areas, including oncology, cardiology, immunology, and endocrine/metabolic diseases